What are brand names of PCSK9 inhibitors?
There are two PCSK9 inhibitors, Repatha (Evolocumab) and Praluent (Alirocumab), and others are being developed at the moment.
How much will PCSK9 inhibitors cost?
The drugs are expensive, costing over $12,000 a year. The major issues concern whether this type of therapy prolongs life and whether it is a good value. The point of view of the patient, health care system and society will influence value assessment. PCSK9 facilitates degradation of the LDL receptor in the hepatocyte.
Are PCSK9 inhibitors covered by insurance?
Note: PCSK9 Inhibitors are typically covered under pharmacy benefit plans. Certain prescription drugs require an authorization for coverage to ensure that appropriate treatment regimens are followed.
How many PCSK9 inhibitors are on the market?
There are currently two FDA approved PCSK9 inhibitors namely, alirocumab and evolocumab available in the United States for adult patients to reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease as an adjunct to diet, alone or …
How do I get PCSK9 inhibitors?
You take PCSK9 inhibitors as an injection. You get the injection in a hospital or at your provider’s office every three months. Every few months, you get a blood test so your provider can see how well the medication is working.
How do I get PCSK9?
How do you qualify for Repatha?
Eligibility Criteria: Subject to program limitations and terms and conditions, the Repatha® Copay Card is open to patients who have a Repatha® prescription and who have commercial or private insurance, including plans available through state and federal healthcare exchanges.
Who is a candidate for Repatha?
Eligible patients with high cholesterol (LDL-C ≥70 mg/dL or non-high-density lipoprotein cholesterol [non-HDL-C] ≥100 mg/dL) and established cardiovascular disease at more than 1,300 study locations around the world were randomized to receive Repatha subcutaneous 140 mg every two weeks or 420 mg monthly plus high- or …
How do you qualify for PCSK9 inhibitors?
The eligibility according ACC criteria was defined: (1) LDL‐C ≥2.6 mmol/L (100 mg/dL) while on statin in combination with ezetimibe and a reduction of LDL‐C levels less than 50% from baseline; or (2) LDL‐C ≥1.8 mmol/L (70 mg/dL) while on statin in combination with ezetimibe and a reduction of LDL‐C levels less than 50% …
Who qualifies for PCSK9 inhibitors?
On the basis of 1‐year LDL‐C levels, lipid‐lowering therapies, and clinical outcomes, the eligibility for the use of PCSK9 inhibitors at follow‐up was defined according to the following ESC/EAS criteria: (1) LDL‐C ≥3.6 mmol/L (140 mg/dL) at 1 year while on statin in combination with ezetimibe; or (2) LDL‐C ≥2.6 mmol/L …
When should I start PCSK9 inhibitors?
In patients with cardiovascular disease at very high risk whose LDL-C level remains ≥70 mg/dL (≥1.8 mmol/L) on a maximally tolerated statin and ezetimibe therapy, adding a PCSK9 inhibitor is reasonable.
Why does Repatha cost so much?
Repatha and Praluent are especially expensive because they would be taken for such a long time. Unlike an antibiotic, which patients take for a few days or weeks, those prescribed Repatha would take it for the rest of their lives.
What is the average cost of Repatha?
The majority of commercial and Medicare plans cover Repatha®. The list price for Repatha® is $519.82*,† per month. Most patients do not pay the list price.
How long do you stay on Repatha?
Therefore most of the medication will be removed from your body between 60.5 days and 93.5 days (approximately 2 to 3 months) which is when you would hope to side effect free.
Can Repatha damage your liver?
Does Repatha cause any liver-related side effects? It’s not likely. In clinical studies, Repatha didn’t cause liver-related side effects, such as an increase in liver enzyme levels or hepatitis (inflammation in your liver).
Is Repatha better than statins?
This clinical trial showed that compared to placebo the combination Repatha reduced LDL-C by 64.4%. The addition of atorvastatin 10mg/d only reduced the LDL-C an extra 0.6%. The atorvastatin 80mg/d with Repatha was actually less effective at reducing LDL-C than just Repatha.